67706-69-8

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 22586-32-9 N-Benzyloxycarbonylglycine imidazolide 
• 6148-64-7 ethyl potassium malonate 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 35116-15-5 Dibasic magnesium salt of ethyl hydrogen malonate 

Downstream Products

• 180295-80-1 (E)-4-Benzyloxycarbonylamino-3-pyrrolidin-1-yl-but-2-enoic acid ethyl ester 
• 67706-71-2 N-Benzyloxycarbonyl-3-hydroxy-4-amino-butyrohydroxamsaeure 
• 1030122-48-5 ethyl 4-benzyloxycarbonylamino-2-hydroxyimino-3-oxo-butyrate 
• 835873-57-9 (E)-4-Benzyloxycarbonylamino-3-(toluene-4-sulfonyloxy)-but-2-enoic acid ethyl ester 
• 835873-56-8 (Z)-4-Benzyloxycarbonylamino-3-(toluene-4-sulfonyloxy)-but-2-enoic acid ethyl ester 
• 159770-29-3 ethyl 5-benzyloxycarbonylaminomethyl-3-methylisoxazole-4-carboxylate 
• 159770-35-1 C₁₇H₁₈N₂O₇ 

Relevant academic research and scientific papers

7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF

The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production

POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

Ru-catalyzed asymmetric hydrogenation of γ-heteroatom substituted β-keto esters

A series of enantiomerically pure γ-heteroatom substituted β-hydroxy esters were synthesized with high enantioselectivities (up to 99.1% ee) by hydrogenation of γ-heteroatom substituted β-keto esters in the presence of Ru-(S)-SunPhos catalyst. These asymmetric hydrogenations provide key building blocks for a variety of naturally occurring and biologically active compounds.

PYRAZOLE COMPOUNDS AND USE THEREOF

The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

1,3-Dipolar cycloaddition route to nitrogen heterocyclic triones

1,3-Dipolar cycloaddition of nitrile oxides, formed in situ by dehydration of primary nitro compounds, with pyrrolidine enamines of protected γ- or δ-amino-β-keto esters affords isoxazole-4-carboxylates; these undergo lactam formation and N-O bond cleavage to afford 3-acyltetramic acids and 3-acyl-4-hydroxypyridin-2-ones.

Process for preparing optically active 4-hydroxy-2-pyrrolidone

A process for preparing optically active 4-hydroxy-2-pyrrolidone comprising asymmetrically hydrogenating an N-substituted-4-amino-3-oxobutanoic ester represented by formula (I): STR1 wherein R1 represents a benzyloxycarbonyl group, the benzene